Commerce Secretary Howard Lutnick said Trump's new tariff policies are focused on ending the U.S.'s reliance on foreign supply of key pharmaceutical products. "We are proud that AstraZeneca has made ...

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs. | Omega Funds has raised $647 million for the investment shop ...

-- For many of these favored stocks, the share prices are close to the consensus price targets, or even exceed them. Most analysts set 12-month price targets. So we made one more cut to 15 stocks for ...

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company ...

Many younger professionals are finding luck launching careers in second-tier cities like Raleigh, Milwaukee and Birmingham, a ...

"We launched the Humankind 100 four years ago to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress," said James ...

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

We look at how the global impact investing market has experienced remarkable growth over the past decade, with emerging ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.